VivoSeq
Oncology

Head and Neck Squamous Cell Carcinoma

259

Pipeline Programs↗

104

Active Trials↗

93

Companies Involved↗

Head and Neck Squamous Cell Carcinoma is a highly competitive landscape with 259 programs across 93 companies. The most active players are Presage Biosciences, Cue Biopharma, Zhuhai Beihai Biotech Co., Ltd. 21 therapies are approved with 38 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

86/100

Pipeline Velocity

54/100

Mech. Concentration

6/100

Completion Rate

62/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Presage Biosciences

1 program

Phase 1C

Cue Biopharma

1 program

Phase 1Z

Zhuhai Beihai Biotech Co., Ltd

1 program

Phase 1Takeda logo

Takeda

1 program

Phase 1BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 1Moderna logo

Moderna

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical6

Nivolumab

Bristol-Myers Squibb

Celecoxib

Philadelphia Eye Associates

Immunotherapy

Bristol-Myers Squibb

Carboplatin (adjuvant）

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Paclitaxel （neoadjuvant）

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 144

Alpelisib

Novartis

Ceralasertib

AstraZeneca

Cyclophosphamide

Baxter Healthcare Corporation

Alisertib

Takeda

Olaparib

AstraZeneca

Phase 2150

Cemiplimab

Regeneron

Abemaciclib

Eli Lilly

Lapatinib

GSK

Tipifarnib

Kura Oncology, Inc.

Camrelizumab

Sun Yat-sen University

Phase 338

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Toripalimab

Coherus Oncology, Inc.

Palbociclib

Pfizer

Nedaplatin

Jiangsu Simcere Pharmaceutical Co., Ltd.

Docetaxel

Avyxa

Approved21

TAZEMETOSTAT

Epizyme, Inc.

Ribociclib

Novartis

Methotrexate

Alnylam Pharmaceuticals

Paclitaxel

Teva

Duvelisib

SecuraBio

Analysis

Modality Breakdown

80%

Small molecule

207 of 258 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody4116%Protein / enzyme42%Antibody–drug conjugate2<1%Radiopharmaceutical2<1%RNA therapy1<1%Vaccine1<1%

Small molecule leads; the ring shows all 258 classified programs, each share of the total. Modality classified for 98% of 282 pipeline programs.

Analysis

Trial Status

243

clinical trials

Completed63 · 26%
Recruiting55 · 23%
Unknown status38 · 16%
Active, not recruiting26 · 11%
Terminated25 · 10%
Not yet recruiting23 · 9%
Other13 · 5%

Clinical Trials

Trial Activity

243 trials

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT06869473·67 enrolled
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Recruiting·—·Phase 1·NCT05747625·60 enrolled
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT03406247·140 enrolled
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05582265·537 enrolled
Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Recruiting·MMegaPro Biomedical Co. Ltd.·Phase 1·NCT06540443·24 enrolled
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
Recruiting·WWest China Hospital·Phase 1·NCT06109207·6 enrolled
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Recruiting·SSun Yat-sen University·Phase 3·NCT06492460·422 enrolled
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Recruiting·PProvidence Health & Services·Phase 2·NCT05913388·92 enrolled
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06668961·60 enrolled
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT06575322·302 enrolled
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Recruiting·—·Phase 3·NCT06496178·500 enrolled
Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study
Recruiting·UUniversity Health Network, Toronto·N/A·NCT02678884·20 enrolled
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 2·NCT06857279·167 enrolled
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Recruiting·GSK logoGSK·Phase 3·NCT06256588·864 enrolled
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06006169·186 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)